Cyh33, a new antitumor drug, has been approved for clinical research

Source: at the beginning of the 2018-1-4 new year in China Science News, good news came from Shanghai Institute of Materia Medica of Chinese Academy of Sciences The research and development of new drugs in the Institute showed a good trend At present, more than 20 clinical new drugs have made good progress It is reported that the cyh33, a new anti-tumor class 1 drug jointly developed by Dingjian research group, yangchunhao research group, menglinghua research group and Shanghai Haihe pharmaceutical research and Development Co., Ltd., was approved by the State Food and Drug Administration for clinical trials Phosphoinositide 3-kinase (PI3K) signaling pathway acts on receptor tyrosine protein kinase and downstream of G-protein-coupled receptor, and plays an irreplaceable regulatory role in tumor development Class I PI3K is divided into four subtypes, among which pi3ka plays a major role in the growth factor stimulated signaling pathway, and only this subtype has active mutations in tumor tissue at a high frequency Pi3ka inhibitor can selectively inhibit the highly activated tumor cells of pi3ka, thus reducing the toxic and side effects The Shanghai Institute of medicine has taken advantage of interdisciplinary advantages and organized key scientific research personnel to jointly tackle key problems Researchers spent more than three years to design, synthesize and screen thousands of compounds, and finally determine the candidate drug cyh33 Cyh33 is a new chemical molecular entity with unique structure It is a highly selective and active inhibitor of pi3ka It has been granted patents in China, the United States, Japan and Canada The preclinical study showed that the antitumor activity of cyh33 in vitro and in vivo was significantly better than that of other similar inhibitors in the world, especially for tumors with Chinese ethnic characteristics It is reported that the research on biomarkers for predicting the efficacy of these drugs carried out at the same time found that the expression profile of receptor tyrosine kinase in breast cancer cells determines the regulation of PI3K on ERK activity, thus determining the sensitivity of breast cancer to pi3ka selective inhibitors, providing an important theoretical basis for the selection of patients in cyh33 clinical trials